Tregalizumab is an immunomodulator.[1] It is also known as BT-061 . Tregalizumab binds to domain 2 of CD4 ,[2] and activates Regulatory T cells (Tregs) .[3]
References
^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF) . WHO Drug Information . 24 (4).
^ Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, et al. (April 2015). "A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway" . Immunology and Cell Biology . 93 (4): 396–405. doi :10.1038/icb.2014.102 . PMC 4407014 . PMID 25512343 .
^ König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J (Jan 2016). "Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells" . Frontiers in Immunology . 7 : 11. doi :10.3389/fimmu.2016.00011 . PMC 4724712 . PMID 26834751 .